Prevention and treatment of stroke in patients with hypertension. <...> Blood pressure reduction, persistence and costs in the evaluation of antihypertensive drug treatment – a review. <...> The economic burden associated with osteoarthritis, rheumatoid arthritis, and hypertension: a comparative study. <...> National estimate of cost of illness for hypertension and non-persistence with drug therapy using the medical expenditure panel survey: dissertation. <...> Theoretical bases of a pharmacoeconomy method: analysis «influences on the budget». <...> Теоретические основы фармакоэкономического метода: анализ «влияния на бюджет». <...> Long-term cost and life-expectancy consequences of hypertension. <...> Pharmacoeconomics and quality of life analysis of telmisartan in hypertension treatment. <...> Expert Review of Pharmacoeconomics and Outcome Research 2007; 7 (5):435–44. <...> The pharmacoeconomy analysis of treatment of arterial hypertension Bisoprolol’s preparations at stationary and out-patient stages. <...> Фармакоэкономический анализ лечения артериальной гипертензии препаратами Бисопролола на стационарном и амбулаторном этапах. <...> Comparative analysis of total disease costs in patients with arterial hypertension: the results of the open, multi-centre observational programme “PRORYV” Tarlovskaya E. <...> To compare total disease costs by the treatment regimen and blood pressure (BP) control levels among patients with arterial hypertension (AH). <...> Pharmacoeconomic analyses of total disease costs were performed for two treatment regimens and 4115 patients participating in the open, multi-centre observational programme “PRORYV”: a retrospective cost analysis for the 12 pre-inclusion weeks and a prospective cost analysis for the 12 weeks of the programme participation. <...> The treatment with a fixed-dose combination of perindopril and amlodipine (Prestance) was more expensive for the patients than the pre-inclusion treatment (955,15±849,96 vs. <...> Switching to <...>